IL149378A0 - Composition for treatment of constipation and irritable bowel syndrome - Google Patents

Composition for treatment of constipation and irritable bowel syndrome

Info

Publication number
IL149378A0
IL149378A0 IL14937800A IL14937800A IL149378A0 IL 149378 A0 IL149378 A0 IL 149378A0 IL 14937800 A IL14937800 A IL 14937800A IL 14937800 A IL14937800 A IL 14937800A IL 149378 A0 IL149378 A0 IL 149378A0
Authority
IL
Israel
Prior art keywords
constipation
bowel syndrome
irritable bowel
composition
treatment
Prior art date
Application number
IL14937800A
Other languages
English (en)
Original Assignee
Rodeva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9925872A external-priority patent/GB9925872D0/en
Priority claimed from GB9928314A external-priority patent/GB9928314D0/en
Application filed by Rodeva Ltd filed Critical Rodeva Ltd
Publication of IL149378A0 publication Critical patent/IL149378A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
IL14937800A 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome IL149378A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9925872A GB9925872D0 (en) 1999-11-01 1999-11-01 Composition for relief of constipation
GB9928314A GB9928314D0 (en) 1999-11-30 1999-11-30 Composition for the treatment of irritable bowel syndrome
PCT/GB2000/004167 WO2001032180A2 (en) 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome

Publications (1)

Publication Number Publication Date
IL149378A0 true IL149378A0 (en) 2002-11-10

Family

ID=26316047

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14937800A IL149378A0 (en) 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome
IL149378A IL149378A (en) 1999-11-01 2002-04-28 Composition for treatment of constipation and irritable bowel syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149378A IL149378A (en) 1999-11-01 2002-04-28 Composition for treatment of constipation and irritable bowel syndrome

Country Status (14)

Country Link
US (1) US6734188B1 (pt)
EP (1) EP1225897B1 (pt)
JP (1) JP2003513045A (pt)
AT (1) ATE275402T1 (pt)
AU (1) AU776567B2 (pt)
CA (1) CA2389650C (pt)
CZ (1) CZ299726B6 (pt)
DE (1) DE60013630T2 (pt)
DK (1) DK1225897T3 (pt)
ES (1) ES2226933T3 (pt)
HK (1) HK1048595A1 (pt)
IL (2) IL149378A0 (pt)
PT (1) PT1225897E (pt)
WO (1) WO2001032180A2 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299283B6 (cs) 1997-12-22 2008-06-04 Euro-Celtique, S. A. Léková forma pro perorální podání
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
NZ535286A (en) 2002-04-05 2007-07-27 Euro Celtique Sa Matrix for sustained, invariant and independent release of active compounds
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
AU2004229462A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
PT2368553E (pt) 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
PT1729797E (pt) * 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1861096B1 (en) 2005-03-07 2018-12-26 The University of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
PL2278002T3 (pl) * 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EP2012790A4 (en) * 2006-04-19 2009-07-01 Smith Jill P TREATMENT OF INFLAMMATORY AND ULCEROUS DISEASES OF THE COLON USING OPIOID ANTAGONISTS
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
BRPI0622008A2 (pt) * 2006-09-13 2011-12-20 Procter & Gamble métodos de tratamento para colite ulcerativa
CA2662430A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
CN101801979A (zh) 2007-03-29 2010-08-11 普罗热尼奇制药公司 (r)-n-溴化甲基纳曲酮的晶体形式及其用途
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2384318T3 (pl) 2008-12-31 2018-04-30 Ardelyx, Inc. Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego
JP5886632B2 (ja) 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． オキシコドンおよびナロキソンを含む即時放出医薬組成物
AU2010238925A1 (en) * 2009-04-22 2011-12-15 Phoeme Gmbh Particulate pharmaceutical composition having an opioid and an opioid antagonist
PE20120991A1 (es) * 2009-09-18 2012-08-01 Adolor Corp Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
RS58969B1 (sr) 2013-04-12 2019-08-30 Ardelyx Inc Jedinjenja koja se vezuju za nhe3 i postupci za inhibiranje transporta fosfata
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN105916505A (zh) 2013-11-13 2016-08-31 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
EP0103636B1 (en) * 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4774230A (en) 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6277413B1 (en) * 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome

Also Published As

Publication number Publication date
DE60013630T2 (de) 2005-09-15
HK1048595A1 (en) 2003-04-11
DE60013630D1 (de) 2004-10-14
AU776567B2 (en) 2004-09-16
CZ20021536A3 (cs) 2003-02-12
DK1225897T3 (da) 2005-01-10
CA2389650C (en) 2008-12-09
US6734188B1 (en) 2004-05-11
WO2001032180A3 (en) 2001-09-20
ATE275402T1 (de) 2004-09-15
CA2389650A1 (en) 2001-05-10
IL149378A (en) 2006-12-31
EP1225897A2 (en) 2002-07-31
CZ299726B6 (cs) 2008-11-05
AU1044701A (en) 2001-05-14
EP1225897B1 (en) 2004-09-08
JP2003513045A (ja) 2003-04-08
ES2226933T3 (es) 2005-04-01
WO2001032180A2 (en) 2001-05-10
PT1225897E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
HK1048595A1 (en) Composition for treatment of constipation and irritable bowel syndrome.
EP1156792A4 (en) METHOD AND COMPOSITION FOR TREATING IRRITABLE COLON SYNDROME WITH LOW DOSES OF OPIOID RECEPTOR ANTAGONISTS
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
HK1091733A1 (en) Pharmaceutical combinations of hydrocodone and naltrexone
HU0003386D0 (en) Use of crf antagonists
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
SI2939696T1 (sl) Polimerni konjugati opioidnih antagonistov
IL149600A0 (en) Novel methods and compositions involving opioids and antagonists thereof
AU2003302603A8 (en) Improved opioid pharmaceutical compositions
IL132760A0 (en) Vibrator for treatment of constipation
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
HK1091141A1 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
AU3452200A (en) Bipolar sensor for muscle tissue action potential duration estimation
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
IL151093A0 (en) Derivatives of quinoline as alpha-2 antagonists
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
IL149650A0 (en) Novel methods for the treatment and prevention of ileus
AU2003299713A8 (en) Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
AU2003247784A8 (en) Compositions and methods for treatment and detection of multiple cancers
AU2002368150A1 (en) Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
WO2000061230A3 (en) Estrogen receptors-beta antagonism and bone diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed